<div class="entities" style="line-height: 2.5; direction: ltr">Admission Date: [**2178-1-20**]        Discharge Date: [**2178-2-7**]<br><br>Date of Birth:  [**2107-2-15**]        Sex:  M<br><br>Service:  OME<br><br><br>HISTORY OF PRESENT ILLNESS:  This patient is a 70-year-old<br>male with extensive locally recurrent 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    melanoma
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 involving his<br>face, status post excision, neck dissection and radiation<br>therapy.  Initial staging was consistent with 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    stage
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    III
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    C
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br>disease but now with mets to the lung, bone and soft tissue.<br>He was due to be started on 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    high
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    -
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    dose
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    IL
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    -
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    2
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 but in clinic on<br>[**2178-1-12**], he was noticed to have erythema in an area of<br>recent lymph node dissection felt consistent with 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    cellulitis
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
,<br>and was started on 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    oral
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    Keflex
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, and now is presenting with<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    worsening
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    erythema
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.  The patient reports that in the week<br>since he started 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    antibiotics
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, the erythema has enlarged and<br>become more red.  In clinic today, his white blood cell count<br>was up to 20,000 and he was admitted to OMED service.<br><br>PAST MEDICAL HISTORY:  Hypertension, 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    metastatic
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    melanoma
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 with<br>original diagnosis in [**2177-6-5**].  On [**2177-8-21**] he underwent<br>wide local excision and sentinel lymph node biopsy, with<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    melanoma
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 present in 1 left intraparotid node.  On [**2177-8-28**]<br>he had re-excision of the left temple and cheek area and a<br>left radical neck dissection, with 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    melanoma
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 in 7 of 69 total<br>lymph nodes.  He underwent radiation therapy to the forehead<br>area, completing 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    20
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Dosage</span>
</mark>
 fractions over 
<mark class="entity" style="background: rgb(46, 204, 113); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    4
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Duration</span>
</mark>
 
<mark class="entity" style="background: rgb(46, 204, 113); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    weeks
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Duration</span>
</mark>
.  He then<br>developed soft tissue nodule superior to the graft, that<br>might have represented residual 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    melanoma
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 and appeared to have<br>reduced in size with radiation.<br><br>In late [**2177-10-6**] a PET CT showed increased 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    glucose
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
<br>uptake at sites of surgery on his thigh and around the<br>superior edge of the graft on his face.  He was seen in<br>follow-up one of three weeks after completion of radiation.<br>Follow up head MRI and torso CT on [**2178-1-7**] revealed no<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    metastatic
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    brain
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    lesions
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
, but metastatic disease in his<br>chest, left axilla, mediastinum and lung, as well as a T12<br>sclerotic focus felt consistent with 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    melanoma
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.  The BRCA<br>mutation testing on his tumor was negative.  He has passed<br>screening tests to begin 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    high
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    -
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    dose
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    IL
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    -
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    2
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 therapy.<br><br>ALLERGIES:  No known drug allergies.<br><br>MEDICATIONS ON ADMISSION:  
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    Enalapril
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    20
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    mg
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    p
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>

<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>

<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    o
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>

<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    daily
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
,<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    pravastatin
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    20
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    mg
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    p
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>

<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>

<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    o
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>

<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    daily
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    Keflex
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    500
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    mg
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    p
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>

<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>

<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    o
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    b
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    i
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    d
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
.<br><br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    PHYSICAL
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 EXAMINATION ON ADMISSION:  Reveals an elderly male<br>in no apparent distress.  HEENT:  Pupils equal, round,<br>reactive to light.  Left temporal and buccal graft without<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    erythema
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.  
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    NECK
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
:  Well-healed scar from posterior auricular<br>area to the left upper chest.  No signs of wound dehiscence.<br>Broad area 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    of
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    erythema
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 and corresponding area warm to touch.<br>No palpable masses or fluid collections.  No cervical,<br>supraclavicular or axillary lymphadenopathy.  HEART:  Regular<br>rate and rhythm, S1, S2.  CHEST:  No dullness to percussion<br>and clear to auscultation bilaterally.  ABDOMEN:  Positive<br>bowel sounds, soft, nontender.  EXTREMITIES:  Warm and well<br>perfused, 1+ edema to [**12-8**] the way up shins bilaterally, 2+ DP<br>and PT pulses.  NEUROLOGIC EXAM:  Nonfocal.<br><br>ADMISSION 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    LABS
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
:  WBC 20.9, hemoglobin 11.7, hematocrit 33.7,<br>platelet count 206,000, BUN 20, creatinine 1.2, sodium 134,<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    potassium
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    6
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    1
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Strength</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    chloride
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    101
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Strength</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    CO2
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    23
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Strength</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    glucose
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 117.<br><br>HOSPITAL COURSE:  The patient was admitted with 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    cellulitis
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>and was placed on 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    IV
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    vancomycin
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
.  
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    Doxycycline
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 was added when<br>he did not appear to be improving.  
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    Unasyn
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 was added when the<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    cellulitic
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    area
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 continued to 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    worsen
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.  He also became short of<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    breath
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 and was treated with 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    Lasix
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
.  Transthoracic echo<br>revealed 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    diastolic
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    heart
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    failure
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 and he was continued on<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    enalapril
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 and 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    Lasix
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
.  He had an ID consult on [**1-28**] who<br>suggested stopping the 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    Unasyn
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, changing to 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    cefepime
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 and<br>adding 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    vancomycin
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 back.  Blood cultures remained negative and<br>he was afebrile throughout this time.  Derm consult on [**1-28**]<br>was obtained due to persistent 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    rash
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
, and a biopsy was<br>performed consistent with 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    melanoma
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.  He was subsequently<br>transferred to the biologic service on [**2178-1-30**] to begin<br>
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    high
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    -
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    dose
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    IL
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    -
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    2
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 therapy.<br><br>During this week he received 7 of 14 doses with 7 doses held<br>related to 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    tachycardia
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-ADE</span>
</mark>
 and 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    pulmonary
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    edema
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.  On treatment day<br>#4, he was 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    tachypneic
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 with 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 to the mid 80s.  Chest x-<br>ray was consistent with 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    bilateral
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    pleural
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    effusions
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.<br>Throughout the day he became increasingly more 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    tachypneic
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 and<br>fatigued, and was transferred to the ICU.  He was treated<br>with 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    Lasix
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 with improvement in his respiratory status.  An<br>echocardiogram on [**2178-2-3**] showed a small pericardial<br>effusion with question tamponade physiology.  Cardiology was<br>consulted and felt they were not able to tap the effusion.<br>He underwent a cardiac MRI on [**2178-2-4**] revealing no cardiac<br>metastases and no tamponade physiology.<br><br>He developed 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    SVT
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 to the 140s on [**2178-2-4**], which<br>spontaneously improved with a 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    fluid
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    bolus
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>
.  His respiratory<br>status improved with continued 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    diuresis
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
, and he was<br>transferred back to the floor on [**2178-2-5**].  
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    Lasix
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 and<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    enalapril
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 were continued and he was weaned to room air with<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    O2
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 saturations in the mid 90s.<br><br>Physical therapy consult was initiated and he was ambulating<br>short distances with a steady gait.  He was discharged to<br>home on [**2178-2-7**] with a plan to follow up in clinic on<br>[**2178-2-10**].<br><br>Other side effects related to 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    IL
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    -
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    2
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 included 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    rigors
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 improved<br>with 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    Demerol
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
; 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
; and 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    hypotension
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 on treatment day 3,<br>requiring 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    fluid
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    boluses
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>
.  During this week he developed acute<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    renal
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    failure
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 with a peak creatinine of 3.0 with associated<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    oliguria
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.  He developed 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    metabolic
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    acidosis
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 with a minimum<br>bicarb of 18, improved with 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    bicarbonate
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    boluses
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>
.<br>Electrolytes were monitored and repleted per protocol.<br>Strict I &amp; Os and serum chemistries were maintained.  
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    IV
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    fluids
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 were continued given acute renal failure.<br><br>During this week he had mild 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    ST
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    elevation
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 to 54, which<br>improved prior to discharge.  He had no hyperbilirubinemia,<br>myocarditis or 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    coagulopathy
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 noted.  He was 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    thrombocytopenic
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-ADE</span>
</mark>
<br>to a 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    platelet
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    count
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    low
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    of
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    68
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
,
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    000
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 without evidence of<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    bleeding
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.  He was 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    anemic
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 and was transfused with 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    packed
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    red
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Drug</span>
</mark>
<br>blood cells with discharge hemoglobin of 9.1.  By [**2178-2-7**]<br>he had recovered from side effects to allow for discharge to<br>home.<br><br>CONDITION ON DISCHARGE:  Alert, oriented and ambulatory.<br><br>DISCHARGE STATUS:  To home with his family.<br><br>DISCHARGE DIAGNOSES:<br>1. 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    Metastatic
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    melanoma
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 status post cycle 1, week 1, high-<br>    dose 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    IL
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    -
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    2
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 therapy complicated by 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    pulmonary
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    edema
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
, and<br>    bilateral 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    pleural
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-ADE</span>
</mark>
 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    effusions
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-ADE</span>
</mark>
 from 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    IL
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    -
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    2
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 induced 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    capillary
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-ADE</span>
</mark>
<br>    
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    leak
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
, with 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    respiratory
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    distress
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.<br>2. 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    Acute
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-ADE</span>
</mark>
 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    renal
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-ADE</span>
</mark>
 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    failure
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-ADE</span>
</mark>
 related to 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    IL
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    -
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    2
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 therapy.<br><br>DISCHARGE MEDICATIONS:  
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    Enalapril
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    20
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    mg
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    p
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>

<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>

<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    o
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>

<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    daily
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    Lasix
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    20
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Strength</span>
</mark>
<br>
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    mg
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    p
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>

<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>

<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    o
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>

<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    daily
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    lorazepam
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    0
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    5
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    mg
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    q
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Frequency</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    6
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    hours
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    p
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Frequency</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Frequency</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    r
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Frequency</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Frequency</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    n
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Frequency</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    nausea
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
,<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    pravastatin
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    20
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    mg
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    p
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>

<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>

<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    o
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>

<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    daily
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    Compazine
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    5
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    to
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    10
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    mg
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    q
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    i
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    d
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
.<br>p.
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    r
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    .
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em;  border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    n
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
. 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; border-radius: 0.35em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699);">
    nausea
    <span style="font-size: 0.8em; font-weight: bold;  border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.<br><br>FOLLOW-UP PLANS:  The patient will return to clinic on<br>[**2178-2-10**] for assessment of his clinical status prior to<br>consideration for treatment with week #2 of therapy.<br><br><br>I have reviewed the discharge summary and agree with the hospital<br>course and disposition as dictated by [**First Name8 (NamePattern2) 622**] [**Last Name (NamePattern1) 17265**].<br><br><br><br>                        [**First Name11 (Name Pattern1) **] [**Last Name (NamePattern1) **], MD [**MD Number(2) 66804**]<br><br>Dictated By:[**Last Name (NamePattern1) 18853**]<br>MEDQUIST36<br>D:  [**2178-2-24**] 12:32:55<br>T:  [**2178-2-25**] 15:33:12<br>Job#:  [**Job Number 87177**]<br><br>cc:[**Numeric Identifier 87178**]</div>